

# James L Riley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2901491/publications.pdf>

Version: 2024-02-01

129  
papers

21,861  
citations

13068

68  
h-index

15683

125  
g-index

130  
all docs

130  
docs citations

130  
times ranked

23523  
citing authors

#	ARTICLE	IF	CITATIONS
1	CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms. <i>Molecular and Cellular Biology</i> , 2005, 25, 9543-9553.	1.1	1,609
2	The CD28 Signaling Pathway Regulates Glucose Metabolism. <i>Immunity</i> , 2002, 16, 769-777.	6.6	1,201
3	SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. <i>Journal of Immunology</i> , 2004, 173, 945-954.	0.4	989
4	Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo. <i>Molecular Therapy</i> , 2009, 17, 1453-1464.	3.7	988
5	Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. <i>Nature Biotechnology</i> , 2008, 26, 808-816.	9.4	916
6	Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 3360-3365.	3.3	758
7	PD-1 signaling in primary T cells. <i>Immunological Reviews</i> , 2009, 229, 114-125.	2.8	655
8	Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation. <i>Journal of Immunology</i> , 2002, 168, 4272-4276.	0.4	652
9	Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells. <i>Science Translational Medicine</i> , 2012, 4, 132ra53.	5.8	555
10	Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells. <i>Science Translational Medicine</i> , 2013, 5, 197ra103.	5.8	539
11	Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor. <i>Clinical Cancer Research</i> , 2011, 17, 4719-4730.	3.2	441
12	Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the Morning. <i>Immunity</i> , 2009, 30, 656-665.	6.6	400
13	Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. <i>Nature Biotechnology</i> , 2002, 20, 143-148.	9.4	395
14	FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 4571-4576.	3.3	370
15	The PDL1-PD1 Axis Converts Human T <sub>H</sub> 1 Cells into Regulatory T Cells. <i>Science Translational Medicine</i> , 2011, 3, 111ra120.	5.8	370
16	Chronic Virus Infection Enforces Demethylation of the Locus that Encodes PD-1 in Antigen-Specific CD8+ T Cells. <i>Immunity</i> , 2011, 35, 400-412.	6.6	357
17	Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 4262-4273.	3.2	339
18	DC-SIGN and DC-SIGNR Bind Ebola Glycoproteins and Enhance Infection of Macrophages and Endothelial Cells. <i>Virology</i> , 2003, 305, 115-123.	1.1	338

#	ARTICLE	IF	CITATIONS
19	Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. <i>Blood</i> , 2016, 127, 1044-1051.	0.6	333
20	Role of PD-1 during effector CD8 T cell differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 4749-4754.	3.3	327
21	Massive ex Vivo Expansion of Human Natural Regulatory T Cells (T <sub>regs</sub> ) with Minimal Loss of in Vivo Functional Activity. <i>Science Translational Medicine</i> , 2011, 3, 83ra41.	5.8	326
22	Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 11790-11795.	3.3	279
23	The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. <i>Blood</i> , 2005, 105, 13-21.	0.6	276
24	CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients. <i>Science Translational Medicine</i> , 2012, 4, 134ra62.	5.8	264
25	Strength of PD-1 signaling differentially affects T-cell effector functions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E2480-9.	3.3	242
26	Engineering Artificial Antigen-presenting Cells to Express a Diverse Array of Co-stimulatory Molecules. <i>Molecular Therapy</i> , 2007, 15, 981-988.	3.7	236
27	Clinical Grade Manufacturing of Human Alloantigen-Reactive Regulatory T Cells for Use in Transplantation. <i>American Journal of Transplantation</i> , 2013, 13, 3010-3020.	2.6	226
28	Antiviral Effect and Ex Vivo CD4+ T Cell Proliferation in HIV-Positive Patients as a Result of CD28 Costimulation. <i>Science</i> , 1996, 272, 1939-1943.	6.0	224
29	Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. <i>Nature Medicine</i> , 2008, 14, 1390-1395.	15.2	224
30	The Inducible Costimulator (ICOS) Is Critical for the Development of Human T <sub>H</sub> 17 Cells. <i>Science Translational Medicine</i> , 2010, 2, 55ra78.	5.8	221
31	Differential Regulation of HIV-1 Fusion Cofactor Expression by CD28 Costimulation of CD4+ T Cells. <i>Science</i> , 1997, 276, 273-276.	6.0	206
32	Generation and Large-Scale Expansion of Human Inducible Regulatory T Cells That Suppress Graft-Versus-Host Disease. <i>American Journal of Transplantation</i> , 2011, 11, 1148-1157.	2.6	192
33	Cd40 Ligand (Cd154) Triggers a Short-Term Cd4+ T Cell Activation Response That Results in Secretion of Immunomodulatory Cytokines and Apoptosis. <i>Journal of Experimental Medicine</i> , 2000, 191, 651-660.	4.2	185
34	Engineering lymphocyte subsets: tools, trials and tribulations. <i>Nature Reviews Immunology</i> , 2009, 9, 704-716.	10.6	185
35	Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. <i>Nature Immunology</i> , 2011, 12, 898-907.	7.0	179
36	Activation of class II MHC genes requires both the X <sup>α</sup> -region and the class II transactivator (CIITA). <i>Immunity</i> , 1995, 2, 533-543.	6.6	176

#	ARTICLE	IF	CITATIONS
37	CAR T cells for infection, autoimmunity and allotransplantation. <i>Nature Reviews Immunology</i> , 2018, 18, 605-616.	10.6	173
38	PSMA-targeting TGF $\beta$ -insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. <i>Nature Medicine</i> , 2022, 28, 724-734.	15.2	171
39	Constitutive cell surface association between CD4 and CCR5. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 7496-7501.	3.3	169
40	Cutting Edge: Foxp3-Mediated Induction of Pim 2 Allows Human T Regulatory Cells to Preferentially Expand in Rapamycin. <i>Journal of Immunology</i> , 2008, 180, 5794-5798.	0.4	167
41	Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand. <i>FASEB Journal</i> , 2004, 18, 1303-1305.	0.2	157
42	CD28 Costimulation Is Essential for Human T Regulatory Expansion and Function. <i>Journal of Immunology</i> , 2008, 181, 2855-2868.	0.4	152
43	CD28 and Inducible Costimulatory Protein Src Homology 2 Binding Domains Show Distinct Regulation of Phosphatidylinositol 3-Kinase, Bcl-xL, and IL-2 Expression in Primary Human CD4 T Lymphocytes. <i>Journal of Immunology</i> , 2003, 171, 166-174.	0.4	146
44	Molecular analysis of G1B and G3A IFN $\beta$ mutants reveals that defects in CIITA or RFX result in defective class II MHC and li gene induction. <i>Immunity</i> , 1994, 1, 687-697.	6.6	136
45	Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. <i>Blood</i> , 2014, 123, 61-69.	0.6	135
46	Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. <i>Blood</i> , 2008, 112, 2847-2857.	0.6	134
47	Steric Shielding of Surface Epitopes and Impaired Immune Recognition Induced by the Ebola Virus Glycoprotein. <i>PLoS Pathogens</i> , 2010, 6, e1001098.	2.1	132
48	Engineering HIV-Resistant Human CD4+ T Cells with CXCR4-Specific Zinc-Finger Nucleases. <i>PLoS Pathogens</i> , 2011, 7, e1002020.	2.1	130
49	FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease. <i>International Immunology</i> , 2007, 19, 825-835.	1.8	124
50	Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. <i>Clinical Immunology</i> , 2010, 136, 348-363.	1.4	124
51	Retinoic Acid and Rapamycin Differentially Affect and Synergistically Promote the Ex Vivo Expansion of Natural Human T Regulatory Cells. <i>PLoS ONE</i> , 2011, 6, e15868.	1.1	118
52	ICOS Costimulation Requires IL-2 and Can Be Prevented by CTLA-4 Engagement. <i>Journal of Immunology</i> , 2001, 166, 4943-4948.	0.4	111
53	Efficient Clinical Scale Gene Modification via Zinc Finger Nuclease-Targeted Disruption of the HIV Co-receptor CCR5. <i>Human Gene Therapy</i> , 2013, 24, 245-258.	1.4	110
54	Large-Scale Production of CD4+ T Cells from HIV-1-Infected Donors After CD3/CD28 Costimulation*. <i>Stem Cells and Development</i> , 1998, 7, 437-448.	1.0	107

#	ARTICLE	IF	CITATIONS
55	Folate Receptor Alpha and Caveolae Are Not Required for Ebola Virus Glycoprotein-Mediated Viral Infection. <i>Journal of Virology</i> , 2003, 77, 13433-13438.	1.5	106
56	Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. <i>PLoS Pathogens</i> , 2017, 13, e1006613.	2.1	106
57	Generation of human islet-specific regulatory T cells by TCR gene transfer. <i>Journal of Autoimmunity</i> , 2017, 79, 63-73.	3.0	102
58	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. <i>Nature Medicine</i> , 2020, 26, 1339-1350.	15.2	96
59	Clinical perspectives for regulatory T cells in transplantation tolerance. <i>Seminars in Immunology</i> , 2011, 23, 462-468.	2.7	95
60	Prostaglandin E2 Impairs CD4+ T Cell Activation by Inhibition of I $\kappa$ B: Implications in Hodgkin's Lymphoma. <i>Cancer Research</i> , 2006, 66, 1114-1122.	0.4	93
61	cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. <i>Journal of Clinical Investigation</i> , 2005, 116, 174-181.	3.9	91
62	Productive Infection of Neonatal CD8+ T Lymphocytes by HIV-1. <i>Journal of Experimental Medicine</i> , 1998, 187, 1139-1144.	4.2	89
63	A Cell-Based Artificial Antigen-Presenting Cell Coated with Anti-CD3 and CD28 Antibodies Enables Rapid Expansion and Long-Term Growth of CD4 T Lymphocytes. <i>Clinical Immunology</i> , 2002, 105, 259-272.	1.4	84
64	Regulatory T Cells and Human Myeloid Dendritic Cells Promote Tolerance via Programmed Death Ligand-1. <i>PLoS Biology</i> , 2010, 8, e1000302.	2.6	81
65	Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. <i>Journal of Clinical Investigation</i> , 2016, 126, 2642-2660.	3.9	81
66	B and T Lymphocyte Attenuator-Mediated Signal Transduction Provides a Potent Inhibitory Signal to Primary Human CD4 T Cells That Can Be Initiated by Multiple Phosphotyrosine Motifs. <i>Journal of Immunology</i> , 2006, 176, 6603-6614.	0.4	76
67	RNA fingerprints provide direct evidence for the inhibitory role of TGF $\beta$ 2 and PD-1 on CD4+ T cells in Hodgkin lymphoma. <i>Blood</i> , 2007, 110, 3226-3233.	0.6	76
68	Naïve and Memory CD4 T Cells Differ in Their Susceptibilities to Human Immunodeficiency Virus Type 1 Infection following CD28 Costimulation: Implications for Transmission and Pathogenesis. <i>Journal of Virology</i> , 1998, 72, 8273-8280.	1.5	71
69	HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. <i>Clinical Immunology</i> , 2003, 106, 16-22.	1.4	70
70	miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. <i>Blood</i> , 2016, 128, 1424-1435.	0.6	70
71	The Paracaspase MALT1 Controls Caspase-8 Activation during Lymphocyte Proliferation. <i>Molecular Cell</i> , 2008, 31, 415-421.	4.5	67
72	Combination Checkpoint Blockade Taking Melanoma Immunotherapy to the Next Level. <i>New England Journal of Medicine</i> , 2013, 369, 187-189.	13.9	65

#	ARTICLE	IF	CITATIONS
73	Mode of Transmission Affects the Sensitivity of Human Immunodeficiency Virus Type 1 to Restriction by Rhesus TRIM5 $\beta$ . <i>Journal of Virology</i> , 2008, 82, 11117-11128.	1.5	63
74	Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo. <i>Nature Medicine</i> , 2020, 26, 1776-1787.	15.2	63
75	Genetic engineering of T cells for immunotherapy. <i>Nature Reviews Genetics</i> , 2021, 22, 427-447.	7.7	63
76	Genetic engineering of T cells for adoptive immunotherapy. <i>Immunologic Research</i> , 2008, 42, 166-181.	1.3	59
77	Human CD8+ T cells do not require the polarization of lipid rafts for activation and proliferation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 15006-15011.	3.3	52
78	Addition of Deoxynucleosides Enhances Human Immunodeficiency Virus Type 1 Integration and 2LTR Formation in Resting CD4 <sup>+</sup> T Cells. <i>Journal of Virology</i> , 2007, 81, 13938-13942.	1.5	52
79	Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. <i>Journal of Translational Medicine</i> , 2011, 9, 131.	1.8	52
80	CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	52
81	Modulation of Susceptibility to HIV-1 Infection by the Cytotoxic T Lymphocyte Antigen 4 Costimulatory Molecule. <i>Journal of Experimental Medicine</i> , 2000, 191, 1987-1998.	4.2	51
82	TCR affinity and specificity requirements for human regulatory T-cell function. <i>Blood</i> , 2012, 119, 3420-3430.	0.6	49
83	Distinct Effects of IL-18 on the Engraftment and Function of Human Effector CD8+ T Cells and Regulatory T Cells. <i>PLoS ONE</i> , 2008, 3, e3289.	1.1	48
84	Adoptive immunotherapy: good habits instilled at youth have long-term benefits. <i>Immunologic Research</i> , 2008, 42, 182-196.	1.3	47
85	Extensive Replicative Capacity of Human Central Memory T Cells. <i>Journal of Immunology</i> , 2004, 172, 6675-6683.	0.4	46
86	Differential Reliance on Lipid Metabolism as a Salvage Pathway Underlies Functional Differences of T Cell Subsets in Poor Nutrient Environments. <i>Cell Reports</i> , 2018, 23, 741-755.	2.9	45
87	The Battle over mTOR: An Emerging Theatre in Host-Pathogen Immunity. <i>PLoS Pathogens</i> , 2012, 8, e1002894.	2.1	44
88	Engineering T Cells to Functionally Cure HIV-1 Infection. <i>Molecular Therapy</i> , 2015, 23, 1149-1159.	3.7	43
89	Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus. <i>PLoS Pathogens</i> , 2016, 12, e1005983.	2.1	43
90	MHC Class II Gene Silencing in Trophoblast Cells Is Caused by Inhibition of CIITA Expression. <i>American Journal of Reproductive Immunology</i> , 1998, 40, 385-394.	1.2	42

#	ARTICLE	IF	CITATIONS
91	Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. <i>Cytotherapy</i> , 2017, 19, 250-262.	0.3	41
92	Selective reactivation of STING signaling to target Merkel cell carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 13730-13739.	3.3	39
93	Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium. <i>Molecular Therapy - Methods and Clinical Development</i> , 2018, 8, 65-74.	1.8	37
94	Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates. <i>Blood</i> , 2020, 136, 1722-1734.	0.6	37
95	Signalling to suit function: tailoring phosphoinositide 3-kinase during T-cell activation. <i>Trends in Immunology</i> , 2007, 28, 161-168.	2.9	36
96	Ligation of CD28 by Its Natural Ligand CD86 in the Absence of TCR Stimulation Induces Lipid Raft Polarization in Human CD4 T Cells. <i>Journal of Immunology</i> , 2005, 175, 7848-7854.	0.4	33
97	Stabilized Human TRIM5 $\alpha$ Protects Human T Cells From HIV-1 Infection. <i>Molecular Therapy</i> , 2014, 22, 1084-1095.	3.7	33
98	Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor. <i>Clinical Immunology</i> , 2005, 115, 26-32.	1.4	32
99	The road to recovery: translating PD-1 biology into clinical benefit. <i>Trends in Immunology</i> , 2007, 28, 48-50.	2.9	32
100	The Potent Oncogene NPM-ALK Mediates Malignant Transformation of Normal Human CD4+ T Lymphocytes. <i>American Journal of Pathology</i> , 2013, 183, 1971-1980.	1.9	32
101	Cutting Edge: A Novel, Human-Specific Interacting Protein Couples FOXP3 to a Chromatin-Remodeling Complex That Contains KAP1/TRIM28. <i>Journal of Immunology</i> , 2013, 190, 4470-4473.	0.4	32
102	Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 133-144.	2.0	29
103	HIV-Resistant and HIV-Specific CAR-Modified CD4+ T Cells Mitigate HIV Disease Progression and Confer CD4+ T Cell Help In Vivo. <i>Molecular Therapy</i> , 2020, 28, 1585-1599.	3.7	29
104	Umbilical Cord Blood Xenografts in Immunodeficient Mice Reveal That T Cells Enhance Hematopoietic Engraftment Beyond Overcoming Immune Barriers by Stimulating Stem Cell Differentiation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1135-1144.	2.0	27
105	Cutaneous T Cell Lymphoma Expresses Immunosuppressive CD80 (B7-1) Cell Surface Protein in a STAT5-Dependent Manner. <i>Journal of Immunology</i> , 2014, 192, 2913-2919.	0.4	27
106	In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines. <i>American Journal of Transplantation</i> , 2017, 17, 3098-3113.	2.6	27
107	CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV. <i>Frontiers in Immunology</i> , 2019, 10, 2310.	2.2	26
108	Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir. <i>Journal of Infectious Diseases</i> , 2017, 215, S160-S171.	1.9	24



#	ARTICLE	IF	CITATIONS
109	The role of co-stimulation in regulation of chemokine receptor expression and HIV-1 infection in primary T lymphocytes. <i>Seminars in Immunology</i> , 1998, 10, 195-202.	2.7	22
110	Kruppel-like Factor 2 Modulates CCR5 Expression and Susceptibility to HIV-1 Infection. <i>Journal of Immunology</i> , 2012, 189, 3815-3821.	0.4	22
111	Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation. <i>Blood Advances</i> , 2021, 5, 1069-1080.	2.5	20
112	HIV Sequence Variation Associated With env Antisense Adoptive T-cell Therapy in the hNSG Mouse Model. <i>Molecular Therapy</i> , 2010, 18, 803-811.	3.7	19
113	Translating In Vitro T Cell Metabolic Findings to In Vivo Tumor Models of Nutrient Competition. <i>Cell Metabolism</i> , 2018, 28, 190-195.	7.2	19
114	Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy. <i>Journal of Infectious Diseases</i> , 2021, 223, S38-S45.	1.9	15
115	NPM1-ALK-Induced Reprogramming of Mature TCR-Stimulated T Cells Results in Dedifferentiation and Malignant Transformation. <i>Cancer Research</i> , 2021, 81, 3241-3254.	0.4	10
116	Influenza Virus Upregulates CXCR4 Expression in CD4+ Cells. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 19-25.	0.5	9
117	CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms. <i>Blood</i> , 2004, 104, 2657-2657.	0.6	9
118	How to kill Treg cells for immunotherapy. <i>Nature Cancer</i> , 2020, 1, 1134-1135.	5.7	7
119	Trafficking and persistence of alloantigen-specific chimeric antigen receptor regulatory T cells in <i>Cynomolgus macaque</i> . <i>Cell Reports Medicine</i> , 2022, 3, 100614.	3.3	7
120	Characterization of CAR T cell expansion and cytotoxic potential during Ex Vivo manufacturing using image-based cytometry. <i>Journal of Immunological Methods</i> , 2020, 484-485, 112830.	0.6	6
121	Engineering T cells to survive and thrive in the hostile tumor microenvironment. <i>Current Opinion in Biomedical Engineering</i> , 2022, 21, 100360.	1.8	5
122	Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model. <i>Journal of Virology</i> , 2017, 91, .	1.5	4
123	Response from Carroll et al.. <i>Trends in Microbiology</i> , 1997, 5, 302-303.	3.5	3
124	The Human CD8 $\beta$ M-4 Isoform Dominant in Effector Memory T Cells Has Distinct Cytoplasmic Motifs That Confer Unique Properties. <i>PLoS ONE</i> , 2013, 8, e59374.	1.1	3
125	Are affinity-enhanced T cells the future of HIV therapy?. <i>HIV Therapy</i> , 2009, 3, 105-108.	0.6	1
126	Quantitation of HIV-1 Entry Cofactor Expression. , 1999, 17, 219-226.		0



#	ARTICLE	IF	CITATIONS
127	Genetically Modified T Cells for Human Gene Therapy. , 0, , 193-205.		0
128	Ultrasensitive antigen density discrimination by synNotch. Cell Research, 2021, 31, 725-726.	5.7	0
129	Engineered ovarian cancer artificial antigen presenting cells (aAPCs) support CD8+T cells growth and function. FASEB Journal, 2008, 22, 519-519.	0.2	0